drugset / Trial / NCT04203901
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2023-09-28
- Completion
- 2023-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMN-001 | Cell therapy | 1e+07 cells | — |
| Background | Everolimus | Small molecule | 5 mg | — |
| Background | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Background | Lenvatinib | Small molecule | 18 mg | — |
| Background | Nivolumab | Monoclonal antibody | 3 mg/kg | — |